Prescriber's Corner

Methylnaltrexone: Peripherally Acting μ-Opioid Receptor Antagonist

Tanya J. Uritsky, PharmD, BCPS, CPE

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Author’s disclosures of conflicts of interest are found at the end of this article.

Tanya J. Uritsky, PharmD, BCPS, CPE, Hospital of the University of Pennsylvania, 3400 Spruce Street, Ground Floor Rhoads Building, Philadelph-ia, PA 19104. E-mail: tanya.uritsky@uphs.upenn.edu


J Adv Pract Oncol 2019;10(1):62–67 | https://doi.org/10.6004/jadpro.2019.10.1.5 | © 2019 Harborside™


  

ABSTRACT

Abstract

Opioid-induced constipation (OIC) is a common adverse effect associated with opioid therapy, with many patients never developing tolerance to this effect. There are many traditional laxatives available to help patients combat this symptom, yet OIC may not reliably respond to conventional treatment. Peripherally acting μ-opioid receptor antagonists (PAMORAs) have a place in the treatment of refractory OIC, when traditional laxatives have not resulted in effective laxation.  There are a number of PAMORAs now available, and methylnaltrexone is the only PAMORA indicated for the treatment of OIC in adults with advanced illness, as well as for patients with chronic noncancer pain, including patients with chronic pain related to prior cancer treatment who do not require frequent opioid escalation. Advanced practitioners need to have an understanding of how and when to best use these medications for the different indications in patients with advanced illness or chronic noncancer-related pain.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.